Johnson & Johnson COVID-19 vaccine
| A vial of Janssen COVID-19 Vaccine | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | Janssen COVID-19 Vaccine,[1][2] COVID-19 Vaccine Janssen[3] |
| Other names | |
| License data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| UNII | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
|
| COVID-19 portal |
.svg){kind=link}
The Johnson & Johnson COVID-19 vaccine is a COVID-19 vaccine[12] that was developed by Janssen Vaccines in Leiden, Netherlands,[13] and its Belgian parent company Janssen Pharmaceuticals,[14] subsidiary of American company Johnson & Johnson.[15][16]
It is a viral vector vaccine based on a human adenovirus that has been modified to contain the gene for making the spike protein of the SARS-CoV-2 virus that causes COVID-19.[3] The body's immune system responds to this spike protein to produce antibodies.[17] The vaccine requires only one dose and does not need to be stored frozen.[18][19]
The vaccine started clinical trials in June 2020, with Phase III trials involving around 43,000 people.[9] On 29 January 2021, Janssen announced that 28 days after a completed vaccination, the vaccine was 66% effective in a one-dose regimen in preventing symptomatic COVID-19, with an 85% efficacy in preventing severe COVID-19,[20][21][22] and 100% efficacy in preventing hospitalization or death caused by COVID-19.[1]
The most common side effects were pain at the injection site, headache, fatigue, muscle aches and nausea.[9][23] Most of these side effects occurred within one to two days following vaccination and were mild to moderate in severity and lasted one to two days.[23][24]
The vaccine has been granted an Emergency Use Authorization by the US Food and Drug Administration[25] and a conditional marketing authorisation by the European Medicines Agency.[11][26][27]